Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UGCG | Q16739 | 3/20 | 0.48 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.46 |
| ▸ | CACNA1G | O43497 | 8/20 | 0.44 |
| ▸ | CACNA1H | O95180 | 8/20 | 0.44 |
| ▸ | CACNA1I | Q9P0X4 | 5/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | ADRA1D | P25100 | 3/20 | 0.37 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.37 |
| ▸ | ADRA1B | P35368 | 3/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29907514 | 0.88 | UGCG (0.45) | UGCGSCN9ACACNA1GCACNA1H | |
| SCHEMBL29601498 | 0.80 | UGCG (0.55) | UGCGSCN9ACACNA1GCACNA1H | |
| SCHEMBL29907547 | 0.79 | UGCG (0.64) | UGCGSCN9ACACNA1GCACNA1HCACNA1I | |
| SCHEMBL29907650 | 0.72 | TSHR (0.41) | UGCGTSHR | |
| SCHEMBL29907410 | 0.70 | UGCG (0.75) | UGCGSCN9A | |
| SCHEMBL29907490 | 0.70 | UGCG (0.75) | UGCGSCN9A | |
| SCHEMBL1434118 | 0.69 | ALDH1A1 (0.59) | TSHR | |
| SCHEMBL22729782 | 0.68 | UGCG (0.43) | UGCGSCN9ATSHRADRA1DADRA1A | |
| SCHEMBL11784830 | 0.68 | ALDH1A1 (0.57) | TSHR | |
| SCHEMBL17859344 | 0.68 | LMNA (0.60) | UGCGCYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220289679-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220289679-A1 | HETEROCYCLIC COMPOUND | GBA1, GBA2, GALC | UGCG 10/4885SCN9A 1952/4885CACNA1G 1281/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.